Acetylation of H3K115 is associated with fragile nucleosomes at CpG island promoters and active regulatory sites

Reviewer #1 (Public review):

Summary:

The authors investigate the role of H3K115ac in mouse embryonic stem cells. They report that H3K115ac localizes to regions enriched for fragile nucleosomes, CpG islands, and enhancers, and that it correlates with transcriptional activity. These findings suggest a potential role for this globular domain modification in nucleosome dynamics and gene regulation. If robust, these observations would expand our understanding of how non-tail histone modifications contribute to chromatin accessibility and transcriptional control.

Strengths:

(1) The study addresses a histone PTM in the globular domain, which is relatively unexplored compared to tail modifications.

(2) The implication of a histone PTM in fragile nucleosome localization is novel and, if substantiated, could represent a significant advance for the field.

Weaknesses:

(1) The absence of replicate paired-end datasets limits confidence in peak localization.

(2) The analyses are primarily correlative, making it difficult to fully assess robustness or to support strong mechanistic conclusions.

(3) Some claims (e.g., specificity for CpG islands, "dynamic" regulation during differentiation) are not fully supported by the analyses as presented.

(4) Overall, the study introduces an intriguing new angle on globular PTMs, but additional rigor and mechanistic evidence are needed to substantiate the conclusions.

Reviewer #2 (Public review):

Summary:

Kumar et al. aimed to assess the role of the understudied H3K115 acetylation mark, which is located in the nucleosomal core. To this end, the authors performed ChIP-seq experiments of H3K115ac in mouse embryonic stem cells as well as during differentiation into neuronal progenitor cells. Subsequent bioinformatic analyses revealed an association of H3K115ac with fragile nucleosomes at CpG island promoters, as well as with enhancers and CTCF binding sites. This is an interesting study, which provides important novel insights into the potential function of H3K115ac. However, the study is mainly descriptive, and functional experiments are missing.

Strengths:

(1) The authors present the first genome-wide profiling of H3K115ac and link this poorly characterized modification to fragile nucleosomes, CpG island promoters, enhancers, and CTCF binding sites.

(2) The study provides a valuable descriptive resource and raises intriguing hypotheses about the role of H3K115ac in chromatin regulation.

(3) The breadth of the bioinformatic analyses adds to the value of the dataset

Weaknesses:

(1) I am not fully convinced about the specificity of the antibody. Although the experiment in Figure S1A shows a specific binding to H3K115ac-modified peptides compared to unmodified peptides, the authors do not show any experiment that shows that the antibody does not bind to unrelated proteins. Thus, a Western of a nuclear extract or the chromatin fraction would be critical to show. Also, peptide competition using the H3K115ac peptide to block the antibody may be good to further support the specificity of the antibody. Also, I don't understand the experiment in Figure S1B. What does it tell us when the H3K115ac histone mark itself is missing? The KLF4 promoter does not appear to be a suitable positive control, given that hundreds of proteins/histone modifications are likely present at this region.

It is important to clearly demonstrate that the antibody exclusively recognizes H3K115ac, given that the conclusion of the manuscript strongly depends on the reliability of the obtained ChIP-Seq data.

(2) The association of H3K115ac with fragile nucleosomes based on MNase-Sensitivity and fragment length, which are indirect methods and can have technical bias. Experiments that support that the H3K115ac modified nucleosomes are indeed more fragile are missing.

(3) The comparison of H3K115ac with H3K122ac and H3K64ac relies on publicly available datasets. Since the authors argue that these marks are distinct, data generated under identical experimental conditions would be more convincing. At a minimum, the limitations of using external datasets should be discussed.

(4) The enrichment of H3K115ac at enhancers and CTCF binding sites is notable but remains descriptive. It would be interesting to clarify whether H3K115ac actively influences transcription factor/CTCF binding or is a downstream correlate.

(5) No information is provided about how H3K115ac may be deposited/removed. Without this information, it is difficult to place this modification into established chromatin regulatory pathways.

At the very least, the authors should acknowledge these limitations and provide additional validation of antibody specificity.

Reviewer #3 (Public review):

Summary:

Kumar et al. examine the H3K115 epigenetic mark located on the lateral surface of the histone core domain and present evidence that it may serve as a marker enriched at transcription start sites (TSSs) of active CpG island promoters and at polycomb-repressed promoters. They also note enrichment of the H3K115ac mark is found on fragile nucleosomes within nucleosome-depleted regions, on active enhancers, and CTCF-bound sites. They propose that these observations suggest that H3K115ac contributes to nucleosome destabilization and so may serve as a marker of functionally important regulatory elements in mammalian genomes.

Strengths:

The authors present novel observations suggesting that acetylation of a histone residue in a core (versus on a histone tail) domain may serve a functional role in promoting transcription, in CPG islands and polycomb-repressed promoters. They present a solid amount of confirmatory in silico data using appropriate methodology that supports the idea that the H3K115ac mark may function to destabilize nucleosomes and contribute to regulating ESC differentiation.

Weaknesses:

Additional experiments to confirm antibody specificity are needed. The authors use synthetic peptides for other markers (e.g., H3K122) to support the claim that the antibody is specific, but ChIP-ChIP assays are performed under cross-linked, non-denatured conditions, which preserve structure and epitope accessibility differently than synthetic peptides used for dot blots. Does the antibody give a single band in western blots of histones, and can the H3K115ac peptide block western and immunofluorescence signals of the antibody? Given that the antibody is a rabbit polyclonal, specificity is not a trivial consideration.

Author response:

Reviewer 1:

Comment 1. The reviewer was under the impression that that we did not perform biological replicates of our ChIP-seq experiments. All ChIP-seq (and ATAC-seq) experiments were performed with biological replicates and the Pearson’s correlations (all >0.9) between replicates were provided in Supplementary Table 1. We had indicated this in the text and methods but will try to make this even clearer.

Reviewer 2:

Comment 2. The reviewer states that our claim of H3K115ac being associated with fragile nucleosomes is based solely on MNase sensitivity and fragment length. This is not correct. Figure 3C and D show the results of sucrose gradient sedimentation experiments, followed by ChIP-seq clearly showing that H3K115ac fractionates with chromatin particles that are enriched for fragile nucleosomes and subnucleosomes. By contrast, H3K115ac is not enriched in stable mononucleosome

Comment 3. The reviewer states that our H3K122ac and H3K64ac comparison rely on publicly available datasets. We would emphasize that these are our own datasets generated and published previously (Pradeepa et. al., 2016) but using exactly the same native MNase ChIP protocol as used here for H3K115ac and processed with identical computational pipelines.

Reviewer 3:

Reviewer 3 is mistaken in thinking our ChIP experiments are performed under cross-linked conditions. As clearly stated in the main text and methods, all our ChIP-seq for histone modifications is done on native MNase-digested chromatin – with no cross-linking. This includes the spike-in experiment shown in Fig S1B to test H3K115ac antibody specificity against the bar-coded SNAP-ChIP® K-AcylStat Panel from Epicypher. We could not include H3K115ac bar-coded nucleosomes in that experiment since they are not available in the panel.

Following that, we would propose to make minor revisions in response to specific reviewer recommendations before posting a version of record. These would include:

(1) Figure 2: title needs change: "H3K115ac marks CpG island promoters poised for activation". this is to make sure it reads with the title for the corresponding section in the main text. Also see: Reviewer 1 comment 7 in Recommendations part.

(2) Figure S2B: legend should read: "Gene ontology analysis for the set of genes analysed in Figure 2C"

(3) Figure F4D: Provide the replicates for western blot

(4) Figure 4A,B: Corrected formatting issues.